-
The Chinese medicine industry has long-term investment value, and these tracks have great potential
Time of Update: 2022-10-01
Traditional Chinese medicine OTC TCM OTC has the characteristics of strong policy immunity, small risk of cost control and price reduction, and because the main sales channel is at the retail end rather than public medical institutions, it has higher price maintenance capabilities, so the industry generally believes that the future expansion of the industry can be expected.
-
China took the lead in formulating and publishing ISO24603, an international standard for stem cells
Time of Update: 2022-10-01
(Reporter Zhang Quan) Led by China, experts from Japan, Germany, Italy, the United Kingdom, the United States and other countries participated in the formulation of the international standard for stem cells ISO24603 "General Requirements for Human and Mouse Pluripotent Stem Cells" The release ceremony was held in Beijing on September 24, which will provide strong support for scientific and technological innovation in the field of stem cells and the development of related industries.
-
11 non-medical insurance, a number of key monitoring varieties, to meet the "eight provinces and two regions" collection
Time of Update: 2022-10-01
The second batch was led by Heilongjiang, and Qinghai and Guizhou were added to the first batch of provinces participating in the procurement of quantity, forming "eight provinces and two regions", 21 varieties entered the collection, a total of 145 pharmaceutical companies participated, and finally 14 pharmaceutical companies selected 16 product specifications, of which the highest price reduction was 92.
-
Announcement of the State Food and Drug Administration on the cancellation of 46 drug registration certificates such as lincomycin hydrochloride capsules (No. 104 [2021])
Time of Update: 2022-10-01
docx to Notice No. 104 [2021] of the State Drug Administration According to the relevant provisions of the Regulations on the Implementation of the Drug Administration Law of the People's Republic of China and the Measures for the Administration of Drug Registration, the State Drug Administration decided to cancel 46 drug registration certificates such as lincomycin hydrochloride capsules.
-
Announcement of the State Food and Drug Administration on the Cancellation of 283 Drug Registration Certificates Including Megestrol Acetate Dispersible Tablets (No. 70 [2021])
Time of Update: 2022-10-01
doc to Announcement No. 70 of 2021 of the State Drug Administration According to the relevant provisions of the Regulations on the Implementation of the Drug Administration Law of the People's Republic of China and the Measures for the Administration of Drug Registration, the State Drug Administration decided to cancel 283 drug registration certificates, including megestrol acetate dispersible tablets.
-
Notice of the State Food and Drug Administration on the Publication of the Catalogue of Generic Drug Reference Preparations (44th Batch) (No. 61 of 2021)
Time of Update: 2022-10-01
doc After the review and confirmation of the Expert Committee on the Consistency Evaluation of Generic Drugs and Efficacy of the State Drug Administration, the Catalogue of Generic Drug Reference Preparations (44th Batch) is hereby published.
-
Pfizer applied to the United States to vaccinate children aged 5 to 11 with an upgraded COVID-19 vaccine booster
Time of Update: 2022-10-01
According to foreign media reports, Pfizer of the United States and German pharmaceutical company BioNTech submitted to the US Food and Drug Administration (FDA) on the 26th local time to apply for authorization for children aged 5 to 11 years old to receive a specially upgraded version of the new crown vaccine booster injection.
-
Announcement of the State Food and Drug Administration on the revision of the drug instructions for enteritinium preparations, indylan oral preparations and ginkgolide injections
Time of Update: 2022-10-01
According to the results of the assessment of adverse drug reactions, in order to further ensure the safety of public medication, the State Drug Administration decided to uniformly revise the [adverse reactions], [contraindications] and [precautions] of the drug instructions such as enteritidin preparation, Yinyuan Huang oral preparation and ginkgolide injection.
-
Inhalant pins change hands, and domestic brands rise! 13 products break through the new medical insurance
Time of Update: 2022-10-01
In the first half of 2022, the brand pattern of sevoflurane for terminal inhalation in public hospitals in key provinces and cities As of now, a total of 5 products have been included in the national collection, and the suspensions for inhalation and terbutaline sulfate atomized inhalation solutions are TOP10 products.
-
How to balance safety and convenience when "online prescription drugs" open the floodgates?
Time of Update: 2022-10-01
↵ Recently, the State Administration for Market Regulation issued the Measures for the Supervision and Administration of Drug Online Sales (hereinafter referred to as the Measures), covering drug net
-
The annual treatment cost of multiple drugs exceeds $1 million!
Time of Update: 2022-10-01
Recently, Bluebird Bio announced that the FDA has accelerated the approval of the company's gene therapy drug Skysona (elivaldogene autotemce, eli-cel), which is used to treat a rare neurological disease cerebral adrenoleukodystrophy (CALD), and is the world's first approved one-time gene therapy for the treatment of early CALD.
-
National insulin special collection landed in Qinghai with an average drop of 48%
Time of Update: 2022-10-01
The Qinghai Provincial Medical Insurance Bureau said that the bureau will do a solid job in listing selected drugs, organizing the signing of purchase and sales contracts, connecting medical insurance payment policies, promoting clinical rational drug use, and strengthening supply testing.
-
The third batch of high-value medical consumables collection and scanning of high-value medical consumables was organized
Time of Update: 2022-10-01
Pharmaceutical and pharmaceutical enterprises Different from the previous two batches of high-value medical consumables, the procurement cycle of orthopedic spine consumables is 3 years, calculated from the actual implementation date of the selection results in each region of the alliance, and the first-year agreement procurement volume is implemented from January to February 2023.
-
The ophthalmic drug track competition has begun, and domestic pharmaceutical companies have not missed the opportunity to dig for gold
Time of Update: 2022-10-01
The industry said that in recent years, with the rise of ophthalmic drug companies in China, domestic enterprises have gradually occupied an important position, of which Kanghong Pharmaceutical and Xingqi Eye Medicine are representatives.
-
Sino Shenzhou helps the cell blue ocean market and boosts new breakthroughs in the cell biological industry
Time of Update: 2022-10-01
On the morning of September 20th, the "2022 (13th) Cell Therapy Conference" co-sponsored by Biovalley, Shanghai Oriental Hospital, Tongji Hospital Affiliated to Tongji University, and Chinese Health S
-
Announcement of the State Food and Drug Administration on the Conversion of Prescription Drugs for Deficiency Deficiency and Thirst-Quenching Agent into Over-the-Counter Drugs (No. 134 [2021])
Time of Update: 2022-10-01
doc According to the "Measures for the Classification and Administration of Prescription Drugs and Non-prescription Drugs (Trial)" (formerly Order No. 10 of the State Drug Administration), after the demonstration and approval organized by the State Drug Administration, the compound was converted from prescription drugs to over-the-counter drugs.
-
The 100 billion ophthalmic drug market will gradually enter the era of innovative drugs
Time of Update: 2022-10-01
) is conducting Phase III clinical trials of NVK002 (one of the core products of Zhaoke Ophthalmology) in Europe and the United States, which is expected to be completed by the end of 2022, and is expected to submit a new drug application to the US Food and Drug Administration in 2023.
-
With the collection of proprietary Chinese medicines, pharmaceutical companies will face new opportunities!
Time of Update: 2022-10-01
On the one hand, after the collection, Chinese medicine enterprises will pay more attention to research and development, continue to increase investment in research and development, focus on the field of research and development of innovative Chinese medicine drugs with more clinical value, or tap the new uses of old products, and develop new drugs with improved Chinese medicine.
-
Autumn and winter influenza superimposed on the new crown Many places provide free vaccinations for key populations
Time of Update: 2022-10-01
People aged 18 years and older can receive both vaccines at the same time Li Tong once told China News Network that two major categories of key populations should pay attention to the prevention of influenza.
-
Surgical robots are included in Medicare, or affect more than 50 billion markets!
Time of Update: 2022-10-01
It is worth mentioning that this is the first provincial document issued nationwide to regulate the surgical robot auxiliary operating system, clarify the medical service charges and medical insurance payment policies, covering orthopedics, head and neck surgery, thoracic surgery, cardiac surgery and many other departments.
